ANAVEX®2-73 treatment resulted in significant increase in the expression of the SIGMAR1 mRNA biomarker that significantly correlated with improvements in the primary and secondary clinical efficacy endpoints CoA (p = 0.029)
The S1R mRNA correlated with the total CDR-COA score. This statement says nothing about whether 30 mg or 50 mg was significantly better than placebo in the primary endpoint. Anavex has never reported the COA scores for the study.
Market Data 
Markets 
AI
